Nausea News and Research

RSS

Nausea is the sensation of unease and discomfort in the upper stomach and head with an urge to vomit. An attack of nausea is known as a qualm.

FDA accepts Eisai's DACOGEN sNDA for review to treat acute myeloid leukemia

Eisai Inc. today announced that the U.S. Food and Drug Administration (FDA) has accepted for review its supplemental New Drug Application (sNDA) seeking approval of DACOGEN (decitabine) for injection in the treatment of acute myeloid leukemia.

13 Jul 2011

Tips for avoiding heat stroke

As a major heat wave sweeps over the country, the University of Alabama at Birmingham Hospital has already treated one patient for heat stroke and is gearing up for more.

13 Jul 2011

Regular exercise may help prevent panic and related disorders

Regular exercise may be a useful strategy for helping prevent the development of panic and related disorders, a new study suggests.

13 Jul 2011

Arena reports APD811 Phase 1 trial results against pulmonary arterial hypertension

Arena Pharmaceuticals, Inc. announced today results from a Phase 1 clinical trial of APD811, an orally bioavailable agonist of the prostacyclin receptor which is intended for the treatment of pulmonary arterial hypertension, or PAH.

13 Jul 2011

FDA-approved Zuplenz oral soluble film now available for licensing to new commercial partners

MonoSol Rx, a specialty pharmaceutical company and the developers of the PharmFilm technology platform, in collaboration with APR Applied Pharma Research s.a. of Switzerland, announced today that its FDA-approved anti-emetic Zuplenz (Ondansetron) oral soluble film is available for licensing to new commercial partners.

11 Jul 2011

Positive top-line results from alemtuzumab Phase 3 trial on multiple sclerosis

Sanofi and its subsidiary Genzyme announced today positive top-line results from CARE-MS I, the first of two randomized, Phase 3 clinical trials comparing the investigational drug alemtuzumab to the approved multiple sclerosis therapy Rebif in patients with relapsing-remitting multiple sclerosis.

11 Jul 2011

Arizona E. coli related death triggers warning

The Center for Disease Control and Prevention (CDC) and the Arizona Department of Health announced last Friday that a man who recently traveled to Germany was infected by the German E. coli outbreak. The man died from kidney complications. This death was the first U.S. fatality of the relentless epidemic. According to the World Health Organization, 52 have been killed in the outbreak.

10 Jul 2011

Onconova, SymBio enter commercialization collaboration for rigosertib in Japan and Korea

Onconova Therapeutics, Inc., and SymBio Pharmaceuticals Limited announced today that they will collaborate to develop and commercialize rigosertib in Japan and Korea. Onconova is conducting late-stage clinical trials with rigosertib (ON 01910.Na) in the U.S., Europe and India for the treatment of Myelodysplastic Syndromes (MDS) and solid tumors.

8 Jul 2011

Novartis Afinitor Phase III trial on tuberous sclerosis meets primary endpoint

Novartis Pharmaceuticals Corporation announced today Phase III trial results that showed more than one-third of patients taking Afinitor tablets experienced a 50% or greater reduction in the size of their subependymal giant cell astrocytomas, non-cancerous brain tumors associated with tuberous sclerosis complex.

8 Jul 2011

Exenatide tQT clinical trial meets pre-specified primary endpoint

Amylin Pharmaceuticals, Inc., Eli Lilly and Company and Alkermes, Inc. today announced results from a thorough QT (tQT) study that assessed the potential of exenatide to increase the QT interval across a wide range of plasma concentrations.

8 Jul 2011

Inhibiting heat shock transcription factor 1 prevents liver cancer in mice

Altering the body's metabolism could be an effective treatment for deadly liver cancer, researchers report.

7 Jul 2011

Tips to help children and teens prepare for games in extreme heat

While many of us are at the shore or in an air conditioned buildings, the student athletes that make us proud throughout the year may be sweating it out on the field this summer.

6 Jul 2011

New 'Fast Track' total hip replacement effective in reducing hospital stay

Discharged from the hospital within two days of a total hip replacement operation? It's possible, thanks to the new 'Fast Track' protocol that underwent testing in the U.S., in response to both patient requests for shorter hospital stays and economic realities of providing medical care.

2 Jul 2011

Checklist to stay healthy and active in summer

The summer is a great season for getting in shape. Whether by playing a sport, doing an aerobic exercise routine, or just returning to that familiar running path -- this is the time for activity.

2 Jul 2011

Fast track protocol reduces hospital costs and infections in total hip replacement surgery

Generally healthy patients who undergo total hip replacement (THR) can be fast tracked to be discharged in two days compared with the standard three to six days, according to a new study by researchers at Hospital for Special Surgery (HSS) in New York City. The study could help cut down on hospital-acquired infections, reduce hospital costs and improve patient satisfaction.

1 Jul 2011

PENNSAID Viscous Solution Phase 2 clinical trial for osteoarthritis pain meets primary endpoint

Nuvo Research Inc., a specialty pharmaceutical company dedicated to building a portfolio of products primarily for the treatment of pain, today announced receipt from Mallinckrodt Inc., a Covidien company (Covidien), of top-line results from a Phase 2 study conducted by Covidien, of twice-daily administration of PENNSAID Viscous Solution (topical diclofenac sodium viscous solution) 2% w/w, previously referred to as PENNSAID Gel.

30 Jun 2011

FDA's ODAC recommends withdrawal of Avastin approval for metastatic breast cancer

Genentech, a member of the Roche Group, announced today that, during a U.S. Food and Drug Administration (FDA) hearing, the FDA's Oncologic Drugs Advisory Committee (ODAC) recommended that the FDA withdraw its approval of Avastin in combination with paclitaxel chemotherapy for previously untreated HER2-negative metastatic breast cancer.

30 Jun 2011

Dendreon receives FDA approval for Los Angeles cancer immunotherapy manufacturing facility

Dendreon Corporation today announced that the U.S. Food and Drug Administration approved its Los Angeles cancer immunotherapy manufacturing facility, allowing the company to continue to increase the availability of PROVENGE across the U.S. to help meet the needs of patients with asymptomatic or minimally symptomatic metastatic castrate resistant prostate cancer.

30 Jun 2011

A.P. Pharma enters into definitive agreements for $24M private placement of common stock and warrants

A.P. Pharma, Inc., a specialty pharmaceutical company, today announced that it has entered into definitive agreements with certain new and existing accredited investors providing for a private placement of common stock and warrants in which the Company will receive $24 million in gross proceeds.

29 Jun 2011

Tibotec, Gilead Sciences enter license agreement for new combination product of PREZISTA and cobicistat

Tibotec Pharmaceuticals today announced that it has entered into a license agreement with Gilead Sciences, Inc., for the development and commercialization of a new once-daily single tablet fixed-dose antiretroviral combination product containing Tibotec's protease inhibitor PREZISTA® (darunavir) and Gilead's cobicistat, an investigational pharmacoenhancing or "boosting" agent.

28 Jun 2011

Nausea News and Research

Further Reading

FDA accepts Eisai's DACOGEN sNDA for review to treat acute myeloid leukemia

Tips for avoiding heat stroke

Regular exercise may help prevent panic and related disorders

Arena reports APD811 Phase 1 trial results against pulmonary arterial hypertension

FDA-approved Zuplenz oral soluble film now available for licensing to new commercial partners

Positive top-line results from alemtuzumab Phase 3 trial on multiple sclerosis

Arizona E. coli related death triggers warning

Onconova, SymBio enter commercialization collaboration for rigosertib in Japan and Korea

Novartis Afinitor Phase III trial on tuberous sclerosis meets primary endpoint

Exenatide tQT clinical trial meets pre-specified primary endpoint

Inhibiting heat shock transcription factor 1 prevents liver cancer in mice

Tips to help children and teens prepare for games in extreme heat

New 'Fast Track' total hip replacement effective in reducing hospital stay

Checklist to stay healthy and active in summer

Fast track protocol reduces hospital costs and infections in total hip replacement surgery

PENNSAID Viscous Solution Phase 2 clinical trial for osteoarthritis pain meets primary endpoint

FDA's ODAC recommends withdrawal of Avastin approval for metastatic breast cancer

Dendreon receives FDA approval for Los Angeles cancer immunotherapy manufacturing facility

A.P. Pharma enters into definitive agreements for $24M private placement of common stock and warrants

Tibotec, Gilead Sciences enter license agreement for new combination product of PREZISTA and cobicistat

Event guide: 4th Extra-Hepatic Lipid-Based Nanoparticles Delivery Summit eBook

Designing fluidic architecture for scalable diagnostic platforms

Evaluating new approaches for rare disease genomics

Expanding access to NMR with the Fourier 80 Duo

Latest News